Surgery Partners SGRY · NASDAQ
$15.90 +3.25% (+$0.50)
Summary
46 / 100 · Bulios Score
What speaks for it
None of the indicators we track stands out on the positive side.
What to watch
- The company made a loss over the last 12 months.
- Operating profit covers the interest on its debt only 1.2 times.
- It missed profit estimates 4 times in the last 8 quarters.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Fairly pricedBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 12% a year over 5 years. Over the last 3 years it grew by 9.2% a year.
Growth in detailDoes it make money?
ReasonablyOver the last 12 months it made a loss of $88.6M.
Profitability in detailIs it financially healthy?
Debt is a burdenRepaying all its debt would take 21.4 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 14
- Hold 8
- Sell 0
Today's price within the analysts' price targets
The average target of $18 is 13% above today's price. 64% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Healthcare Organization, Patient Service 49%
- Private Insurance 26%
- Government Revenue 21%
- Self-Pay Revenue 1.3%
- Other Services 1.3%
- Other 1.1%
By region
- IDAHO 100%
Healthcare Organization, Patient Service brings in 49% of revenue. Other Services grew fastest, by 29% a year.
Segments in detail